Mesoblast (ASX:MSB) Total Operating Expense: A$0.00 Mil (TTM As of Dec. 2025)


ASX:MSB Mesoblast Ltd ASX:MSB
46 GF Score
Price A$1.95
! 4 Warning Signs
View Full Analysis

What is Mesoblast Total Operating Expense?

Mesoblast ASX:MSB +3.45% 46 Total Operating Expense is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:MSB with a GF Score™ of 46/100. The stock has 4 warning signs investors should review.

Mesoblast's Total Operating Expense for the three months ended in Dec. 2025 was A$0.00 Mil. Mesoblast's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.

Mesoblast Total Operating Expense Related Terms

Mesoblast Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Mesoblast's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast Total Operating Expense Chart

Mesoblast Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 150.47 129.95 114.42 96.19 114.45

Mesoblast Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:MSB
46GF Score
Mesoblast Ltd ASX:MSB
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mesoblast Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of A$0.00 Mil mean?
Mesoblast (ASX:MSB) has a Total Operating Expense of A$0.00 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Mesoblast and its competitors.
Is Mesoblast's Total Operating Expense too high?
Mesoblast's current Total Operating Expense is A$0.00 Mil. Overall, Mesoblast has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's Total Operating Expense compare to VRTX and REGN?
Mesoblast's Total Operating Expense of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Mesoblast and its competitors. Mesoblast's current Total Operating Expense is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (ASX:MSB) has a current Total Operating Expense of A$0.00 Mil. The current Total Operating Expense is A$0.00 Mil. Mesoblast's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Mesoblast (ASX:MSB), the current Total Operating Expense is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
46GF Score

Get the complete analysis for ASX:MSB

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.95
Price